Research Results

Perth – October 14, 2026 -- Sun Silver Limited (ASX: SS1; OTCQX: SSLVF) recovered 84.5% of silver and 83.6% of gold within 24 hours in cyanide leach testwork on its Maverick Silver Project in Nevada, strengthening the case for a tank-leach/CIL processing route alongside heap leach.

Sample 1 test delivers peak recoveries within 48 hours

The top result came from Sample 1 (LT15), run at a P80 53μm grind with 5,000 ppm initial and 2,500 ppm maintained sodium cyanide and no lead nitrate. Head assay recoveries were 84.5% for silver and 83.6% for gold, with peak recoveries indicated between 0 and 48 hours. Most recoverable metal in the test was extracted in the first 24 hours.

Interim solution assays for Sample 1 pointed to higher extraction at 24 and 48 hours than the reported figures, which are calculated from final head assay grades. The company notes that interim extractions are indicative point-in-time calculations, not final recoveries.

Indianapolis – October 14, 2026 -- Carnyx Therapeutics Ltd. unveiled CNYX-005, an oral sleep candidate that increased total sleep time by roughly 1.5 to 2 hours in aged rats versus a control arm, as the preclinical-stage company moves toward clinical development.

The increase was driven primarily by more non-rapid eye movement (NREM) sleep. Researchers measured sleep architecture using continuous electroencephalography (EEG) monitoring.

Carnyx hires Chris Brearley, M.D., as Chief Medical Officer ahead of clinical entry

Brearley brings more than 30 years of experience in translational medicine, clinical pharmacology and early-stage drug development. His prior roles include senior positions at Pfizer, Amgen and Serono. He has designed and overseen first-in-human and early-stage clinical studies, the stage CNYX-005 now approaches.

Brearley said he aims to translate the findings into a rigorous clinical development program.

Los Angeles – October 12, 2026 -- TED patients with pre-existing hearing loss were more than 60% less likely to suffer a further hearing decline when teprotumumab (TEPEZZA) infusions were spaced six weeks apart instead of the standard three, according to a retrospective study presented at the ASOPRS 57th Annual Fall Scientific Symposium.

Hearing decline hit 45% of patients on the standard schedule at 24 weeks

Nine of 20 patients (45%) on the standard three-week schedule showed a clinically significant decline on formal audiometry at 24 weeks. On the six-week schedule, the rate was about one in six. Clinical significance was defined using American Speech-Language-Hearing Association (ASHA) criteria.

The symposium ran October 8-9, 2026, at the Hyatt Regency New Orleans. Shoaib Ugradar, MD, was the presenting author. The study was led by Raymond Douglas, MD, PhD.